RCT is a world leader in nonexclusive licensing. In the life sciences, we have built a portfolio of enabling gene expression technologies through our GXT Program. We have also built a presence in ultrasound imaging with the patented Tissue Harmonic Imaging technology and in digital printing with the patented Blue Noise Mask halftoning technology.
The RCT BioVentures program provides venture capital to companies whose technologies have the potential to become significant biomedical products. Our current investment interests include novel therapeutics, devices and medical technology platforms.
Early-stage technologies often cannot justify the expense of creating a traditional company to develop them. RCT offers vital capital, management and a variety of flexible development options to advance promising new drugs, devices and diagnostics into clinical trials.